These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 24345266)

  • 1. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.
    Al-Nema MY; Gaurav A
    Curr Top Med Chem; 2020; 20(26):2404-2421. PubMed ID: 32533817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.
    Rajagopal L; Massey BW; Huang M; Oyamada Y; Meltzer HY
    Curr Pharm Des; 2014; 20(31):5104-14. PubMed ID: 24345269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.
    Remington G; Agid O; Foussias G
    Expert Rev Neurother; 2011 Apr; 11(4):589-607. PubMed ID: 21469931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
    Boggs DL; Carlson J; Cortes-Briones J; Krystal JH; D'Souza DC
    Curr Pharm Des; 2014; 20(31):5077-92. PubMed ID: 24345265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.
    Brown JW; Rueter LE; Zhang M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Mar; 49():53-62. PubMed ID: 24269664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
    Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
    Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive deficit in schizophrenia and its neurochemical basis.
    Breier A
    Br J Psychiatry Suppl; 1999; (37):16-8. PubMed ID: 10211135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targets for treating cognitive dysfunction in schizophrenia.
    Gray JA; Roth BL
    Schizophr Bull; 2007 Sep; 33(5):1100-19. PubMed ID: 17617664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric aspects of phosphodiesterases: An overview.
    Murthy VS; Mangot AG
    Indian J Pharmacol; 2015; 47(6):594-9. PubMed ID: 26729948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.
    Girgis RR; Van Snellenberg JX; Glass A; Kegeles LS; Thompson JL; Wall M; Cho RY; Carter CS; Slifstein M; Abi-Dargham A; Lieberman JA
    J Psychopharmacol; 2016 May; 30(5):428-35. PubMed ID: 26966119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive impairment as a target for pharmacological treatment in schizophrenia.
    Davidson M; Keefe RS
    Schizophr Res; 1995 Sep; 17(1):123-9. PubMed ID: 8541245
    [No Abstract]   [Full Text] [Related]  

  • 19. Treating impaired cognition in schizophrenia.
    Ibrahim HM; Tamminga CA
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1587-94. PubMed ID: 22283754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Concepts in Dopamine D
    Urs NM; Peterson SM; Caron MG
    Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.